Discusses Social Impact, Global Health Initiatives, and Sustainability Strategy December 1, 2025 10:00 AM ESTCompany ...

TSRA-196 is a potential one-time treatment to precisely correct the genetic mutation underlying AATD, with Investigational New Drug filing expected by the end of the year Tessera to receive $150 ...

Armed conflicts continue to expose millions of children to life-threatening risks, including acute injuries, infectious ...

Background Recurrent mitral regurgitation (MR) remains a major limitation of mitral valve (MV) repair in patients with ...

Nutrition plays a central role for public health outcomes, influencing the prevention and management of chronic diseases and contributing to overall ...

The Trump administration has slashed funding for medical research, delaying some treatments and cures for health conditions ...

Introduction Black and Asian women experience significantly higher rates of mortality and morbidity perinatally compared with white women and are more likely to lose their babies. These groups are ...

Approval based on Phase 3 trials showing Dupixent significantly reduced itch and hives at 24 weeks compared to placebo In the EU, there are approximately 270,000 adults and adolescents aged 12 years ...

Sanofi and Regeneron’s Dupixent approved as the first targeted medicine in the EU in over a decade for chronic spontaneous urticaria Approval ...

Approval based on Phase 3 trials showing Dupixent significantly reduced itch and hives at 24 weeks compared to placebo In the EU, there are approximately 270,000 adults and adolescents aged 12 years ...

Sanofi and Regeneron's Dupixent approved as the first targeted medicine in the EU in over a decade for chronic spontaneous urticaria Approval based on phase 3 studies showing Dupixent significantly ...

Although some outcomes showed small to medium effect sizes, these results must be interpreted cautiously given the presence ...